- Home
- ATAI vs HYI Comparison
ATAI vs HYI Comparison
Compare ATAI & HYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ATAI | HYI |
|---|---|---|
| Founded | 2018 | 2010 |
| Country | Netherlands | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 251.4M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | ATAI | HYI |
|---|---|---|
| Price | $4.10 | $11.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $14.33 | N/A |
| AVG Volume (30 Days) | ★ 3.2M | 50.6K |
| Earning Date | 11-12-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.59% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,018,000.00 | N/A |
| Revenue This Year | $943.18 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 811.78 | N/A |
| 52 Week Low | $1.15 | $10.99 |
| 52 Week High | $6.75 | $12.24 |
Technical Indicators
Market Signals| Indicator | ATAI | HYI |
|---|---|---|
| Relative Strength Index (RSI) | 45.25 | 48.86 |
| Support Level | $3.88 | $10.96 |
| Resistance Level | $4.72 | $11.07 |
| Average True Range (ATR) | 0.25 | 0.05 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 23.81 | 83.38 |
Price Performance
Historical ComparisonAbout ATAI ATAI Life Sciences N.V.
Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.
About HYI Western Asset High Yield Defined Opportunity Fund Inc.
Western Asset High Yield Defined Opps. is a non-diversified, limited-term, closed-end management investment company. The company's investment objective is to provide high income and seek capital appreciation. The fund invests a majority of its net assets in a portfolio of high-yield corporate fixed-income securities issued or originated by U.S. or foreign public or private corporations and other business entities, with varying maturities.